Climb Bio Widens Loss as Pipeline Spend Builds Toward 2028
Climb Bio's net loss grew 55.8% to $13.5 million in the second quarter, even as a $110 million private placement pushed cash reserves to $239.2 million and extended its runway into the second half of 2028.
Climb Bio (CLYM) reported a net loss of $13.5 million, or $0.18 a share, for the second quarter of 2026, widening from $8.7 million, or $0.13 a share, a year earlier. The clinical-stage biopharmaceutical company attributed the larger loss to higher research and development spending as two of its lead programs advanced toward mid-stage data readouts.
Research and development expenses rose 47.7% to $9.7 million in the quarter from $6.6 million in the prior-year period, while general and administrative costs climbed 37.6% to $5.6 million from $4.1 million. The quarterly increase came even as six-month R&D spending fell 20.1% to $19.1 million from $23.9 million in the first half of 2025, a divergence that reflects front-loaded spending earlier in 2025 rather than a slowdown in current program activity.
Other income, net was roughly flat at $1.9 million, down slightly from $2.0 million a year earlier, as the company's cash balance grew but yields moderated.
Climb Bio's cash position expanded sharply during the quarter. Cash, cash equivalents and marketable securities rose 48.9% to $239.2 million at June 30, 2026, from $160.7 million at the end of 2025, driven by a $110 million private placement the company completed on April 29, 2026. The proceeds extend its cash runway into the second half of 2028.
The added capital funds a pipeline that is entering a run of clinical milestones. The company's CLYM116 program, targeting IgA nephropathy, is expected to begin dosing in a Phase 2 trial in the third quarter of 2026, alongside a parallel Phase 2 dosing effort from partner Mabworks also slated for the third quarter. Budoprutug's PrisMN Phase 2 trial has advanced into its second dosing cohort at 600 milligrams following an initial 200-milligram cohort, with initial B-cell and anti-PLA2R data expected in the fourth quarter of 2026.
Climb Bio also disclosed a board change during the quarter. Breanna O'Reilly, Ph.D., of RA Capital Management joined the board in June 2026, replacing Dr. Andrew Levin.
With cash now funding operations well into 2028, Climb Bio's near-term narrative turns on whether the CLYM116 and budoprutug data expected later this year and into 2028 justify the accelerating spend.